Clinical trial · Observational
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Renal Cell Carcinoma Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Medication usage
- timeFrame
- From start point for 2.5 months
- measure
- Treatment's duration
- timeFrame
- From start point for 2.5 months
Secondary outcomes (4)
- measure
- Cost of medication used
- timeFrame
- From start point for 2.5 months
- measure
- Costs of adverse event management
- timeFrame
- From start point for 2.5 months
- description
- (total calculated costs attributed to Adverse Effects (AEs) management according to the attached list of adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with confirmed diagnosis of clear-cell renal cell carcinoma * Patients with evidence of metastatic disease * Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib * Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease Exclusion Criteria: * Patients enrolled in any clinical trial involving anti-cancer therapy * Pregnant woman
References
Publications (0)
Data not yet available